Autoplaque vs CAC Software
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your clinical workflow requires a comprehensive, AI-powered quantitative analysis of both coronary plaques and luminal stenoses from CT angiography images. This tool is ideal for detailed characterization of atherosclerotic plaque beyond just calcification, providing insights crucial for advanced heart attack risk prediction and guiding specific treatment strategies.
View Autoplaque →Choose CAC Software if…
Choose CAC Software if your primary need is the automated quantification of coronary artery calcification from non-contrast chest CT scans. This solution is best suited for efficiently generating Agatston scores, arterial age, and calcified lesion mass/volume, enabling rapid risk assessment for coronary artery disease in a screening or general diagnostic setting.
View CAC Software →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | CAC Software |
|---|---|---|
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Cloud-based (SaaS), integrates with PACS |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CAC SoftwareImbio's CAC Software offers superior usability by integrating seamlessly into existing DICOM viewing workflows and operating as a fully automated software platform with no user input required for processing. This minimizes disruption to current clinical practice. Autoplaque, while offering interactive features and clinician editing, is workstation-based, which may require a separate application launch and more active user engagement.
Clinical Value
AutoplaqueAutoplaque provides a more comprehensive clinical assessment by performing quantitative analysis of coronary plaques (including calcified, non-calcified, and low-attenuation plaque) and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. While Imbio's CAC Software provides valuable Agatston scores for calcification, it does not directly assess non-calcified plaque, which is increasingly recognized for its role in cardiovascular risk.
Pricing & Value
TieNeither Autoplaque nor Imbio's CAC Software publicly discloses its pricing information. Both require direct contact with the company for pricing details, making a head-to-head comparison on this dimension impossible. Therefore, no winner can be determined.
Enterprise Readiness
CAC SoftwareImbio's CAC Software demonstrates stronger enterprise readiness with flexible deployment options, including cloud, on-premise, and partner platforms. Crucially, it explicitly states HIPAA compliance (third-party certified) and offers a Business Associate Agreement (BAA), addressing key requirements for data security and privacy in large healthcare organizations. Autoplaque's workstation-based deployment and lack of specified BAA/HIPAA compliance information present potential limitations for enterprise-wide adoption.
Innovation
AutoplaqueAutoplaque exhibits greater innovation by focusing on the detailed characterization of various coronary plaque types, including non-calcified and low-attenuation plaque, and the measurement of luminal stenoses from CT angiography. This goes beyond traditional calcification scoring to offer a more advanced and nuanced approach to cardiovascular risk prediction and treatment guidance. Imbio's CAC Software, while utilizing deep learning, primarily automates a well-established calcification scoring method.
Support & Docs
CAC SoftwareImbio provides clear and comprehensive support options, including 24/7/365 email and website support, dedicated phone support during business hours, and readily available user manuals and product documentation upon request. Autoplaque's information on customer support channels and documentation is not specified in the provided data or readily available through web searches.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | CAC Software |
|---|---|---|
| Name | Autoplaque | CAC Software |
| Company | Cedars-Sinai Medical Center: AIM | Imbio |
| Description | Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | Imbio's Coronary Artery Calcification (CAC) software is a set of automated image post-processing algorithms designed to help radiologists and cardiologists determine the location and calculate the amount of calcification within the coronary arteries in patients who have undergone a non-contrast, chest computed tomography (CT). |
| Key Features | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images; Workstation-based post-processing application; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician); Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views; Measurement of vessel diameter and area | Automated image post-processing for coronary artery calcification; Quantification of calcification within coronary arteries; Outputs Agatston score, arterial age, calcified lesion mass and volume; Provides 3D visualizations and annotated images; Non-invasive analysis from non-contrast chest CT scans; Integrates into existing DICOM viewing workflow; Supports risk assessment for coronary artery disease; Deep-learning based analysis |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and CAC Software.